1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Green Cross Holdings Corporation

Green Cross Holdings Corporation

005250.KS
Green Cross Holdings CorporationKR flagKorea Exchange
11,340.00
KRW
-770.00
- -
509.55BMarket Cap
Green Cross Holdings Corporation
005250.KS
(Korea Exchange)

Recent

price

11,340.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
19,192.99
19,038.98
19,817.77
20,903.04
22,895.76
24,902.17
29,830.24
32,260.63
34,033.25
33,239.47
38,145.71
40,694.28
44,919.94
45,996.9
48,548.05
53,992.94
55,248.82
Revenue per Share
1,557.09
644.59
1,426
974
1,245
1,439
1,039
955
406
65.82
3,793
1,222
709
-1,210
529
-1,531
-1,990.16
Basic EPS, GAAP
7,294.31
1,288.58
-1,093.58
-2,001.2
-820.46
-3,696.1
-3,970.22
-1,466.85
-2,426.45
-3,501.9
-2,217.22
-841.62
-648.53
-3,850.4
-3,251.54
-2,769.85
-1,169.47
Free Cash Flow per Basic Share
209.82
504.21
435.81
585.68
412.98
469.94
525.7
485.92
486.18
406.79
476.08
712.77
680.42
669.03
559.98
731.36
36.66
Dividend per Share
5,518.6
12,274.38
13,356.96
13,474.54
14,172.87
15,359.21
16,111.78
16,763.44
16,925.22
16,854.23
20,668.79
21,456.97
21,265.28
20,603.91
20,304.38
18,327.07
17,796.8
Book Value per Share
19,022.17
19,118.94
21,554.44
23,495.95
24,591.98
27,262.77
28,517.04
29,185.68
29,005.05
30,386.2
30,135.8
30,428.02
28,072.95
26,516.7
26,142.84
22,871.55
21,819.5
Tangible Book Value per Share
43
43
43
45
46
45
45
45
45
45
45
45
46
45
45
45
45
Basic Weighted Avg Shares
832,291
817,435
855,345
934,622
1,043,840
1,132,120
1,354,466
1,464,875
1,547,971
1,493,589
1,719,326
1,840,559
2,079,560
2,057,936
2,204,855
2,451,476
2,491,670
Sales/Revenue/Turnover
19.68
14.39
10.26
9.76
10.95
9.44
7.33
7.6
3.14
4.47
4.12
4.69
3.46
-0.8
-0.49
1.49
1.77
Operating Margin (%)
26,016
20,135
17,026
20,452
26,045
31,506
35,099
41,244
47,282
56,942
52,831
62,443
78,656
94,846
103,742
107,166
108,427
Depreciation Expense
67,522
27,675
61,547
43,550
56,761
65,421
47,177
43,364
18,467
2,957
170,960
55,270
32,823
-54,136
24,025
-69,513
-89,754
Net Income, GAAP
28.21
34.92
53.85
25.68
27.56
28.11
25.71
26.44
55.13
63.52
34.8
29.08
- -
- -
126.08
- -
34.44
Effective Tax Rate (%)
8.11
3.39
7.2
4.66
5.44
5.78
3.48
2.96
1.19
0.2
9.94
3
1.58
-2.63
1.09
-2.84
-3.6
Profit Margin (%)
2,072,964
344,367
211,616
297,394
402,116
586,294
615,800
622,280
482,804
447,314
433,027
498,952
209,624
-151,962
106,062
-61,120
-96,233
Working Capital
179,619
145,215
30,506
61,104
52,113
124,752
251,057
450,651
414,876
469,659
218,821
434,715
483,207
251,653
432,002
583,832
614,910
LT Debt
839,832
895,760
972,827
1,099,667
1,181,067
1,307,379
1,377,011
1,439,668
1,453,117
1,506,596
1,673,501
1,910,729
1,967,044
1,881,542
1,852,175
1,763,769
1,719,289
Total Equity
12.4
6.41
3.34
5.48
5.95
4.87
4.13
4.05
0.99
1.05
1.84
2.22
- -
- -
0.09
- -
- -
Return on Invested Capital (%)
3.87
0.8
3.17
0.97
1.44
1.66
1.65
1.34
1.18
1.88
7.18
0.09
- -
- -
1.39
- -
1.22
Return on Capital (%)
32.14
7.22
11.15
7.39
9.09
9.73
6.6
5.81
2.41
0.39
20.24
5.81
3.36
-5.68
2.61
-7.93
-10.53
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,011,706
909,464
1,007,616
LT Borrowings
462,010
475,510
504,166
LT Finance Leases
111,589
108,322
110,744
Preferred Equity and Hybrid Capital
1,257
1,257
1,257
Shares Outstanding
45
45
45
Market Capitalization
706,463
716,363
601,170

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,645,283
1,546,885
1,563,872
Cash, Cash Equivalents & STI
120,812
99,283
101,928
Accounts Receivable, Net
586,942
477,924
441,056
Inventories
868,385
909,796
928,838
Total Current Liabilities
1,686,634
1,608,005
1,660,105
Payables & Accruals
- -
- -
- -
ST Debt
1,011,706
909,464
1,007,616
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.2%
1.29%
-4.77%
Free Cash Flow
37.76%
72.32%
-14.84%
Net Income, GAAP
459.64%
-181.39%
-389.34%
Sales/Revenue/Turnover
8.24%
7.47%
11.19%
Total Cash Common Dividend
6.29%
11.7%
30.57%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
469,999
559,774
609,984
565,098
2,204,855
2025
494,577
600,552
736,861
619,487
2,451,476
2026
534,771
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-912
-367
-24
- -
529
2025
65
755.15
203.96
- -
-1,531
2026
-381
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
559.98
2025
- -
- -
- -
- -
731.36
2026
36.39
- -
- -
- -
- -
Similar Companies
Idera Pharmaceuticals, Inc. (IDRA)
Jilin Jian Yisheng Pharmaceutical Co., Ltd. (002566.SZ)
Genomic Valley Biotech Ltd. (GVBL.BO)
Strategic Partners A/S (STRAP.CO)
Genfit S.A. (GNFT)
Sorrento Therapeutics, Inc. (SRNEQ)
Business
Green Cross Holdings Corporation functions as a prominent biotechnology enterprise, overseeing a portfolio of affiliates dedicated to healthcare solutions. The company provides a diverse array of biopharmaceutical products, including vital plasma-derived therapies and an extensive range of vaccines for infectious diseases like influenza, varicella, and hepatitis B. Beyond these, its offerings extend to specialized prescription medications, treatments for rare conditions such as Hunter syndrome and emerging therapies for Sanfilippo syndrome, alongside various over-the-counter health items. Actively engaged in advanced research and development, Green Cross Holdings focuses on groundbreaking areas like oncology, immunology, and innovative cell therapies. Recent strategic advancements include its expansion into the United States market with plasma products, notably with 'Aliglo' receiving regulatory approval and initiating exports in 2024, further solidified by the acquisition of US plasma collection centers to ensure a stable supply of raw materials. The company also continues to forge partnerships to accelerate the development and global reach of its cell therapy innovations. Established in 1967, Green Cross Holdings maintains its headquarters in Yongin, South Korea.